Cartherics has two autologous CAR-T products, treating cutaneous T cell lymphoma and ovarian cancer, entering clinical trials in 2023-24. The lead allogeneic product is expected to enter clinical trials for ovarian cancer in 2025. There is a pipeline of additional products focused on solid tumours following close behind. The Cartherics platform is expected to bring significant options for effective therapy across a wide spectrum of cancer types.